Kinetics, distribution, and sites of destruction of indium-111 oxine labelled red cells in haemolytic anaemia

A DU P HEYNS, MG LÖTTER, HF KOTZÉ, P WESSELS, H PIETERS, PN BADENHORST

From the Blood Platelet Research Unit of the University of the Orange Free State and the South African Medical Research Council and the Department of Biophysics, Bloemfontein 9300, Republic of South Africa

SUMMARY The survival of red cells labelled with indium-111 oxine in the circulation was determined. In vivo distribution at equilibrium and sites of deposition at the T50In—that is, the half life of labelled red cells—were quantitated with a scintillation camera and computer assisted image analysis. Although the rate of elution of 111In from the red cells was higher than that of chromium-51-disodium chromate, estimates of T50In and T50Cr corresponded reasonably well and were shortened in haemolytic anaemia. In normal subjects red cells were sequestered mainly in the liver and spleen. In five patients with different types of haemolytic anaemia two distinct patterns of red cell sequestration could be recognised: mainly splenic sequestration, and destruction of red cells in the liver, spleen, and the bone marrow. These patterns were expected for the particular disease studied.

The determination of the life span and the sites of sequestration of red cells is often a useful adjunct in the investigation of a patient with haemolytic anaemia. The recommended method for these studies is labelling of a random cell population with chromium-51-disodium chromate (51Cr).12 Although the 320 keV photons of 51Cr is adequate for in vitro counting and permits external monitoring of organ radioactivity, this radionuclide has several disadvantages. The elution rate from red cells is significant and may be 5% per day in patients.3 The 10% photon yield of 51Cr is too low for imaging the in vivo isotope distribution and determining organ radioactivity with external detectors is unreliable.13

Indium-111 oxine (111In) is an alternative blood cell label.4 111In has 90% and 94% γ emissions per disintegration for the 172 and 247 keV photon energies, respectively, which facilitates imaging of the in vivo distribution of isotope labelled cells. Labelling efficiency of red cells is high (greater than 90%) and 80% of the 111In is bound to haemoglobin and 20% to membrane.5 Although the relatively high binding to red cell membrane makes considerable elution of radionuclide from the erythrocyte likely, it was nevertheless thought worthwhile to evaluate the clinical usefulness of estimates of life span and quantification of sites of destruction of 111In labelled erythrocytes. The patients selected were considered likely to illustrate different patterns of reticuloendothelial system sequestration of red cells. Although several technical and interpretative problems emerged, the advantages of measuring accurately the in vivo distribution of labelled red cells may make the technique useful in clinical practice.

Patients and methods

PATIENTS AND CONTROLS The relevant details of the five patients are given in Table 1. All were in a haematological steady state as reflected by a constant haemoglobin concentration and reticulocyte count during the investigation. Five healthy young adults, one man and four women, acted as controls.

LABELLING OF RED CELLS Blood (17-5 ml) was collected into a syringe containing 2-5 ml of acid citrate dextrose. Three millilitres of a 6% solution of hydroxyethyl starch was added and the syringe left upright for 1 h. Theuffy coat and plasma were removed. The red cells were washed three times with 10 ml normal saline and centrifuged at 180 g for 10 min. The erythrocytes

Accepted for publication 9 October 1984
Kinetics, distribution, and destruction of indium-111 oxine labelled red cells in haemolytic anaemia

Table 1  Clinical details and red cell survival and scintigraphic data

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age</th>
<th>Diagnosis</th>
<th>Haemoglobin concentration (g/dl)</th>
<th>Reticulocyte count (×10^6/l)</th>
<th>'111In administered (MBq)</th>
<th>Red cell survival data 5'Cr (days)</th>
<th>5'Cr T50Cr (days)</th>
<th>5'In T50In (days)</th>
<th>Scintigraphy: pattern of sequestration</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 1st</td>
<td>Male 60</td>
<td>140-16-2</td>
<td>13-2</td>
<td>420</td>
<td>14-9</td>
<td>11-5</td>
<td>7-3</td>
<td>Mainly splenic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 1st</td>
<td>Male 65</td>
<td>10-100</td>
<td>8-5</td>
<td>696</td>
<td>12-2</td>
<td>3-0</td>
<td>2-5</td>
<td>Mainly splenic (Fig. 1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 1st</td>
<td>Male 17</td>
<td>7-8</td>
<td>9-0</td>
<td>580</td>
<td>12-2</td>
<td>14-9</td>
<td>7-2</td>
<td>Liver; spleen; bone marrow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 1st</td>
<td>Male 62</td>
<td>7-9</td>
<td>6-7</td>
<td>657</td>
<td>14-7</td>
<td>7-8</td>
<td>5-1</td>
<td>Liver; spleen; bone marrow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 1st</td>
<td>Male 52</td>
<td>3-0</td>
<td>9-5</td>
<td>396</td>
<td>14-1</td>
<td>7-9</td>
<td>5-3</td>
<td>Mainly in liver; also spleen and bone marrow</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Normal subjects

Range or mean (SD)

14-0-16-2 | 10-100 | 15-0 (0-5) | 28-7 (7-5) | 13-2 (3-0) | Mainly in liver and spleen; bone marrow not visualised |

were suspended in 10 ml of saline, approximately 18-6 MBq (500 μCi) 111In-oxine (Radiochemical Centre, Amersham) was added, and the cells were incubated for 5 min at 37°C. The erythrocytes were washed three times in saline and resuspended in 5 ml of autologous platelet poor plasma for reinjection.

Labelling of red cells with 51Cr was performed as recommended by the ICSH.1

RED CELL LIFE SPAN

This is expressed as the T50Cr and T50In—that is, the time taken for half of the radioactivity to leave the circulation.

The rate of elution of 111In from red cells was estimated from the mathematical model, assuming that all circulating red cells have the same potential life span and are subject to random destruction at a constant rate.1

IMAGING AND QUANTIFICATION OF DISTRIBUTION OF 111In LABELLED RED CELLS

Image acquisition and quantification of 111In labelled red cell distribution were performed with a scintillation camera interfaced with a computer assisted image processing system using the method previously described for platelet studies.5 7

Briefly, anterior and posterior whole body 111In radioactivity was measured 30 min after reinjection of labelled cells and daily for nine days. Regions of interest were selected by computer analysis, and the radioactivities of the spleen and liver were determined. The region of interest 111In radioactivity was corrected for attenuation by the geometrical mean method—that is, calculating the square root of the product of the anterior and posterior measurements. Region of interest radioactivity is expressed as a percentage of the whole body geometrical mean count. The relation between changes in whole body and region of interest 111In radioactivity with time was determined by least square regression analysis of data. Radioactivity of regions of interest at equilibrium and at the red cell T50In was derived by extrapolation of the regression line.

STATISTICAL METHODS

Student’s t test was used to test for differences between means.

RESULTS

RED CELL SURVIVAL

The relevant clinical, laboratory, and red cell survival data are given in Table 1.

Red cell half life was shortened in all patients; results of T50Cr and T50In corresponded reasonably well in some patients, but in others there were striking differences.

In the normal subjects the T50In of 13-2 ± 3-0 days was considerably shorter than that of 51Cr (28-7 ± 7-5 days). The elution rate of 111In from red cells in the normal subjects was high and estimated to be 7-9% per day.

SITES OF DESTRUCTION OF 111In LABELLED RED CELLS

The 111In radioactivity of the whole body, spleen, and liver at equilibrium and at the T50In are given in Table 2. The organ distribution at T50In is illustrated in the scintographs of Figs. 1 and 2 and described in Table 1.

CONTROLS

Whole body radioactivity decreased significantly with time (p < 0-001) and was variable. Splenic radioactivity increased by about half at T50In whereas that of the liver doubled.

PATIENTS

Whole body radioactivity also decreased
Table 2  Organ and whole body $^{111}$In radioactivity at equilibrium and at $T_{sl}$In

<table>
<thead>
<tr>
<th></th>
<th>Spleen</th>
<th>Liver</th>
<th>Spleen:liver</th>
<th>Whole body</th>
<th>Spleen</th>
<th>Liver</th>
<th>Spleen:liver</th>
<th>Whole body</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equilibrium</td>
<td>17-9</td>
<td>8-0</td>
<td>2-2</td>
<td>100</td>
<td>23-7</td>
<td>13-8</td>
<td>1-7</td>
<td>74-9</td>
</tr>
<tr>
<td></td>
<td>14-1</td>
<td>9-1</td>
<td>1-6</td>
<td>100</td>
<td>36-8</td>
<td>13-4</td>
<td>2-8</td>
<td>92-1</td>
</tr>
<tr>
<td></td>
<td>10-4</td>
<td>10-4</td>
<td>1-0</td>
<td>100</td>
<td>9-3</td>
<td>18-1</td>
<td>0-5</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>12-2</td>
<td>7-8</td>
<td>1-6</td>
<td>100</td>
<td>10-5</td>
<td>14-5</td>
<td>0-7</td>
<td>92-8</td>
</tr>
<tr>
<td></td>
<td>7-7</td>
<td>30-0</td>
<td>0-3</td>
<td>100</td>
<td>13-2</td>
<td>26-4</td>
<td>0-5</td>
<td>81-5</td>
</tr>
<tr>
<td>Controls</td>
<td>2-9</td>
<td>9-0</td>
<td>0-3</td>
<td>100</td>
<td>1-5</td>
<td>24-8</td>
<td>0-06</td>
<td>76-6</td>
</tr>
<tr>
<td></td>
<td>3-4</td>
<td>12-7</td>
<td>0-3</td>
<td>100</td>
<td>6-4</td>
<td>29-4</td>
<td>0-2</td>
<td>96-1</td>
</tr>
<tr>
<td></td>
<td>3-0</td>
<td>9-2</td>
<td>0-3</td>
<td>100</td>
<td>5-3</td>
<td>24-5</td>
<td>0-2</td>
<td>85-2</td>
</tr>
<tr>
<td></td>
<td>2-4</td>
<td>11-2</td>
<td>0-2</td>
<td>100</td>
<td>4-2</td>
<td>31-6</td>
<td>0-1</td>
<td>72-5</td>
</tr>
<tr>
<td></td>
<td>2-7</td>
<td>11-6</td>
<td>0-2</td>
<td>100</td>
<td>6-0</td>
<td>20-4</td>
<td>0-3</td>
<td>79-7</td>
</tr>
<tr>
<td>Mean (1SD)</td>
<td>2-9 (0-4)</td>
<td>10-7 (1-6)</td>
<td>0-26 (0-05)</td>
<td>100 (0)</td>
<td>4-7 (2-0)</td>
<td>26-1 (4-4)</td>
<td>0-17 (0-09)</td>
<td>81-0 (10-1)</td>
</tr>
</tbody>
</table>

Organ $^{111}$In radioactivity is expressed as a percentage of whole body radioactivity.

Fig. 1 Anterior scintigraph of the distribution of $^{111}$In radioactivity at the $T_{sl}$In in a patient with congenital spherocytosis (patient 1). The accumulation of radioactivity especially in the spleen is obvious. Note that the bone marrow is not visualised. The activities in the heart and liver are of about equal intensity.

Fig. 2 Anterior scintigraph of the distribution of $^{111}$In radioactivity at the $T_{sl}$In in a patient with cold agglutinin disease (patient 4). The liver, spleen, and pelvis are clearly seen.
Kinetics, distribution, and destruction of indium-111 oxine labelled red cells in haemolytic anaemia

significantly with time (p < 0.001), was variable, but was of the same magnitude as that of the controls. At equilibrium, the splenic 111In activity was much higher in all the patients than that of the controls (p < 0.0005), but liver activity was high only in patient 5. These findings are also reflected by the respective spleen to liver ratios.

Two patterns of red cell destruction could be recognised: considerable cell sequestration in the spleen (patients 1 and 2) and sequestration diffusely in all components of the reticuloendothelial system (patients 5, 4, and 3). These patterns are reflected by the T50In organ radioactivity and the spleen to liver ratios (Table 2) and are illustrated in the scintigraphs (Figs. 1 and 2).

Discussion

Since 111In has a physical half life of only 2.8 days it cannot replace 51Cr as a radiopharmaceutical for the determination of red cell survival. 111In, however, has strikingly superior physical properties and its high gamma emission makes in vivo quantification and scintigraphic visualisation of isotope distribution possible. The new technology of computer assisted imaging also permits accurate selection and delineation of organs and other regions of interest. This methodology has been applied successfully in quantitative studies of platelet kinetics.

In normal subjects it appears that the liver and spleen are major sites of destruction of senescent red cells. That radioactivity not in the liver or spleen at the T50In may reflect some bone marrow sequestration of red cells, but because of the diffuse distribution of the marrow this could not be quantitated or visualised. At the T50In there are also appreciable numbers of labelled red cells in the circulation and this will obviously contribute to the background radioactivity. The high rate of elution of 111In may also influence the results: injected free 111In localises especially in the liver but also in the spleen and the bone marrow. Also, after uptake of cell bound isotope there is a slow redistribution of 111In from the spleen to the liver, presumably as plasma 111In. It is therefore apparent that hepatic 111In activity may increase progressively with time and may be falsely high. It also follows that splenic and especially bone marrow 111In radioactivity will indeed reflect uptake by these organs of spent or damaged red cells. Obviously, in subjects with normal red cell survival quantification of red cell distribution at the T50In is seriously impaired by the short half life of 111In.

Many of these problems become less pronounced when the red cell survival is shortened. The results in the five patients with haemolytic anaemia were as expected for the specific disease. The splenic sequestration in congenital spherocytosis (patient 1) and IgG antibody mediated autoimmune haemolytic anaemia (patient 2) was clearly reflected by the quantitative data and the scintigraphic images. In this small series it was easy to separate these patients from patients 3, 4, and 5 with a pattern of sequestration of red cells mainly in the liver, but also in the spleen and the bone marrow. This diffuse reticuloendothelial system sequestration pattern was characterised by a moderate increase in the spleen to liver ratio and a scintigraph clearly showing all three organs (Fig. 2).

The methodology of the quantification of in vivo distribution of 111In with the geometrical mean method for correction of attenuation has been verified and found to be accurate to within about 6%.10 11 The radiation dose to the critical organs is also acceptable for human studies.12 13 The elution rate of 111In from reticuloendothelial cells is low—that is, only about 2% of the initial splenic activity per day.14 The measurement of 111In accumulation in the spleen, liver, and bone marrow should reflect mainly uptake of red cells in the organs and not redistribution of isotope.

Several problems should, however, be recognised when interpreting the data. The half life of 111In is short relative to red cell survival time, and this makes estimates of red cell life span inaccurate, especially in normal subjects. The rate and variation of elution of 111In from the red cell are important, especially when red cell survival is normal or only slightly reduced.1 The estimated rate of elution (7-9% per day) of 111In is high compared with the loss of about 1% of 51Cr per day.1 The elution from abnormal cells may also vary.1 This high rate of elution of 111In from the red cells is clearly reflected by the short T50Cr as compared with the T50Cr in normal subjects (Table 1). Since 20% of 111In is bound to the red cell membrane,3 the pathological processes involved in red cell destruction may also affect the rate of elution.

Despite these reservations the results of the study of red cell kinetics of 111In oxine labelled cells in patients with haemolytic anaemia are promising, and it may be a suitable method of forecasting the response to splenectomy. Quantification of in vivo distribution of 111In labelled red cells is made possible by the application of the modern technology of the scintillation camera and a computer assisted imaging system. The limitations imposed by the high rate of elution of the radionuclide will be overcome if a ligand that binds indium firmly to red cells is found.

This project was supported by the South African
Medical Research Council and the Central Research Fund of the University of the Orange Free State. The secretarial assistance of Mrs E Herbst is gratefully acknowledged.

References


Requests for reprints to: Professor A du P Heyns, Blood Platelet Research Unit, Department of Haematology, PO Box 339 (G2), Bloemfontein 9300, Republic of South Africa.